Together with the parental cell line TF-1 (ATCC® CRL-2003™), the IDH2R140Q human isogenic leukemia cell line provides an ideal model for studying tumor-associated IDH2 mutation and its impact during cellular growth, metabolism and epigenetic regulation.
IDH1 and IDH2 mutations are seen in glioma and acute myeloid leukemia as well as in many human cancers. These are cancer driver genes that cause a gain-of-function in tumor cells. IDH is a metabolic enzyme that interconverts isocitrate and alpha-ketoglutatrate in the TCA cycle. Cancer-associated point mutations seen in IDH1 and IDH2 confer neomorphic activity resulting in the reduction alpha-KG to the oncometabolite 2-hydroxyglutarate or 2-HG. High concentrations of 2HG have been shown to inhibit alphaKG-dependent dioxygenases, including histone and DNA demethylases which alter epigenetic regulation leading to cellular differentiation and tumorigenesis.
|Date Created||10/03/2017 12:02 PM
|Date Updated||10/03/2017 12:03 PM